News Home

Should Biotechnology Stock Hepion Pharmaceuticals Inc (HEPA) Be in Your Portfolio Friday?

Friday, May 27, 2022 01:03 PM | InvestorsObserver Analysts
Should Biotechnology Stock Hepion Pharmaceuticals Inc (HEPA) Be in Your Portfolio Friday?

The 42 rating InvestorsObserver gives to Hepion Pharmaceuticals Inc (HEPA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 53 percent of stocks in the Biotechnology industry, HEPA’s 42 overall rating means the stock scores better than 42 percent of all stocks.

Overall Score - 42
HEPA has an Overall Score of 42. Find out what this means to you and get the rest of the rankings on HEPA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Hepion Pharmaceuticals Inc Stock Today?

Hepion Pharmaceuticals Inc (HEPA) stock is trading at $0.76 as of 1:02 PM on Friday, May 27, a rise of $0.04, or 5.05% from the previous closing price of $0.72. The stock has traded between $0.73 and $0.76 so far today. Volume today is less active than usual. So far 72,663 shares have traded compared to average volume of 234,703 shares. Click Here to get the full Stock Report for Hepion Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App